BILL ANALYSIS

HR6894

BULLISH

Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025

HR6894 (Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025) has been assessed with a bullish outlook for investors. This legislation directly affects $AMN. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bullish

Market Sentiment

1

Affected Stocks

1

Sectors Impacted

Key Takeaways for Investors

1

HR 6894 is a low-probability, early-stage scope-of-practice bill with zero authorized funding.

2

AMN Healthcare ($AMN) has marginal upside if bill passes, via expanded demand for mid-level practitioners in cardiac rehab.

3

Labcorp ($LH) is structurally unaffected; the bill does not alter lab testing or diagnostics coverage.

4

No current market pricing reflects this bill — AMN's 12.43% 30-day gain is from broader staffing recovery trends.

5

Passage requires referral through two House committees, floor votes in both chambers, and presidential action — unlikely in 2025-2027.

How HR6894 Affects the Market

No actionable market impact today. AMN ($20.62) is already pricing in sector recovery independent of HR 6894. LH ($262.99) remains driven by diagnostic testing demand, competitive dynamics with Quest Diagnostics ($DGX), and reimbursement policy, not by this rehabilitation scope bill. Investors should monitor committee activity — a markup or hearing would be the first real signal of legislative momentum. Without one, this bill is noise for retail portfolios.

Bill Details

MetricValue
Bill NumberHR6894
Market Sentimentbullish
Event Date
Affected SectorsHealthcare
Affected Stocks$AMN
SourceView on Congress.gov →

Summary

HR 6894 is an early-stage, low-probability bill that expands Medicare cardiac and pulmonary rehab supervision to PAs, NPs, and CNSs. It authorizes zero funding and remains in committee. Marginal upside for healthcare staffing firm AMN (allied health demand) is possible but contingent on passage. Labcorp (LH) sees no structural impact. Current market prices: AMN $20.62, LH $262.99.

Full AI Market Analysis

What happened: On December 18, 2025, Rep. Sewell (D-AL) introduced HR 6894, the 'Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025.' The bill amends the Social Security Act to allow physician assistants, nurse practitioners, and clinical nurse specialists to prescribe exercise, prepare treatment plans, and supervise cardiac and pulmonary rehab programs under Medicare Part B. The bill was referred to both the Energy and Commerce and Ways and Means Committees. An identical companion bill (S717) exists in the Senate. The bill has only one cosponsor, Rep. Smith of Nebraska (R-NE), and has seen no further action since referral. The money trail: This bill authorizes zero new funding. It is a scope-of-practice expansion, not an appropriations bill. It does not change Medicare reimbursement rates for rehab services, nor does it increase the number of covered sessions. The mechanism is purely regulatory — it expands the pool of practitioners who can independently manage these programs. Any revenue impact flows from increased patient throughput, not from new direct spending. Structural winners and losers: The primary potential beneficiaries are healthcare staffing firms like AMN Healthcare ($AMN) that place mid-level practitioners. Expanded scope could increase demand for PAs/NPs in outpatient cardiac rehab settings. Labcorp is listed but has minimal direct exposure — the bill does not alter lab testing requirements or coverage. Larger healthcare systems and hospital chains (HCA, THC) could see marginal volume increases if implementation increases patient enrollment, but these effects are small and distant. Real market data context: AMN trades at $20.62, up 12.43% over 30 days but still well below its 52-week high of $23.74. The recent uptrend appears driven by broader healthcare staffing recovery, not HR 6894. LH at $262.99 is down 1.43% over 30 days and 0.31% over 7 days, reflecting sector headwinds unrelated to this bill. Timeline: The bill is in the earliest legislative stage with only one House cosponsor and no committee hearings. Passage probability in the 119th Congress is low given the narrow scope and absence of funding. The identical Senate companion (S717) adds minimal momentum. Procedural hurdles: House committee markup, floor vote, Senate committee, floor vote, and presidential signature remain, all requiring bipartisan cooperation in a divided Congress.

Stocks Affected by HR6894

Sectors Impacted by HR6894

Related Healthcare Legislation

Understand the Terms

Free — no credit card

Know which stocks HR6894 moves — before the market does

HillSignal scores every bill, federal contract, and insider filing for market impact and emails you the high-conviction ones. Free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →